Bottom line
PJP vs RSPH: the short answer
PJP (Invesco Pharmaceuticals ETF) and RSPH (Invesco S&P 500 Equal Weight Health Care ETF) are quite different portfolios: only about 21% of their top holdings (by weight) are shared.
RSPH is cheaper at 0.4% vs 0.58% — a difference of $18 a year per $10,000 invested.
Over five years, PJP returned +9.0% a year vs +4.7% for RSPH.
Updated Nov 19, 2026
PJP vs RSPH side by side
| PJP | RSPH | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | Invesco | Invesco |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.58% | 0.4% |
| Annual cost per $10k | $58 | $40 |
| 10-yr cost on $10k (prospectus) | $726 | $505 |
| Max front load | None | None |
| 12b-1 fee | — | — |
| 1-yr return | +27.9% | +9.3% |
| 5-yr return (annualized) | +9.0% | +4.7% |
| 10-yr return (annualized) | +5.1% | +8.2% |
| Best quarter | +18.1% | +17.5% |
| Worst quarter | −14.8% | −14.3% |
| Net assets (fund) | $472.1M | $766.9M |
| Number of holdings | 33 | 63 |
| Portfolio turnover | 36% | 24% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | PJP | RSPH | Difference |
|---|---|---|---|
| 2025 | +27.9% | +9.3% | +18.6% |
| 2024 | +9.7% | −0.8% | +10.5% |
| 2023 | −2.2% | +3.9% | −6.2% |
| 2022 | −2.0% | −9.2% | +7.2% |
| 2021 | +14.5% | +23.0% | −8.6% |
| 2020 | +11.2% | +18.9% | −7.7% |
| 2019 | +4.7% | +25.3% | −20.7% |
| 2018 | −1.7% | −0.3% | −1.4% |
| 2017 | +15.3% | +23.4% | −8.1% |
| 2016 | −19.3% | −4.5% | −14.8% |
Source: Fund prospectus bar charts
Holdings overlap
6 of PJP's top 25 holdings also appear in RSPH's top 25.
| Holding | PJP | RSPH |
|---|---|---|
| Abbott Laboratories | 5.67% | 1.83% |
| AbbVie Inc. | 5.48% | 1.73% |
| Amgen Inc. | 5.33% | 1.77% |
| Regeneron Pharmaceuticals, Inc. | 3.14% | 1.96% |
| Bristol-Myers Squibb Co. | 2.94% | 1.82% |
| Viatris Inc. | 2.83% | 1.72% |
Source: SEC Form N-PORT
PJP top 10
- Invesco Private Prime Fund — 7.93%
- Abbott Laboratories — 5.67%
- AbbVie Inc. — 5.48%
- Amgen Inc. — 5.33%
- Johnson & Johnson — 5.18%
- Merck & Co., Inc. — 5.06%
- Eli Lilly and Co. — 5.02%
- Corcept Therapeutics Inc. — 4.96%
- Gilead Sciences, Inc. — 4.53%
- Pfizer Inc. — 4.50%
RSPH top 10
- Bio-Techne Corp. — 2.13%
- IQVIA Holdings Inc. — 2.00%
- Baxter International Inc. — 1.99%
- Regeneron Pharmaceuticals, Inc. — 1.96%
- Mettler-Toledo International Inc. — 1.94%
- Charles River Laboratories International, Inc. — 1.93%
- Veeva Systems Inc. — 1.93%
- DaVita Inc. — 1.87%
- Moderna, Inc. — 1.85%
- Thermo Fisher Scientific Inc. — 1.84%
FAQ
What is the difference between PJP and RSPH?
Which is cheaper, PJP or RSPH?
Should I own both PJP and RSPH?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.